EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A live-cell medium-throughput assay for quantifying lipid accumulation in hepatocytes

Mun C D Ko, Cameron J Nowell, Sarah M Turpin-Nolan, Bernard L Flynn

Methods · 2027-01 · 257 · 32-42

DOI: 10.1016/j.ymeth.2026.10.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Methods, 2027-01. Verfasst von Mun C D Ko und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global health burden contributing to the high prevalence of associated metabolic diseases such as cardiovascular disease and thus global mortality rates. MASLD is diagnosed by ≥ 5 % lipid accumulation in the liver, and candidate therapies are often evaluated for lipid lowering effects. Current cell-based lipid imaging approaches rely on fixed-cell staining with dyes such as BODIPY 493/503, limiting the ability to dynamically monitor lipid accumulation in living hepatocytes. To gain a better understanding of the effect of different culture conditions and pharmacological interventions on lipid dynamics, we have developed a live-cell assay of fatty acid stimulated lipid accumulation utilising BODIPY 493/503, in two hepatocyte cell lines (HepG2 and AML12) with a simplified workflow. This workflow was validated by its success in helping characterise the lipid lowering activity of known pharmacological agents under different conditions and as a function of time. The agents included impact both lipid biosynthesis (diacylglycerol acyltransferase and acetyl-CoA carboxylase inhibitors) and metabolism (THR-β agonist). Collectively, this assay enables the temporal interrogation of hepatic lipid dynamics and represents a valuable tool for screening and characterising emerging MASLD therapeutics.

Schlagwörter

Stichwörter der Autor:innen

BODIPY 493/503Drug discoveryLipid accumulationLive-cell imagingMedium-throughput screeningMetabolic-associated steatotic liver disease

Autor:innen und Institutionen

  • Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.
  • Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.
  • Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia. Electronic address: Bernard.flynn@monash.edu.

Zitieren

APA

Ko, M. C. D., Nowell, C. J., Turpin-Nolan, S. M., & Flynn, B. L. (2027). A live-cell medium-throughput assay for quantifying lipid accumulation in hepatocytes. Methods, 257, 32-42. https://doi.org/10.1016/j.ymeth.2026.10.006

Vancouver

Ko MCD, Nowell CJ, Turpin-Nolan SM, Flynn BL. A live-cell medium-throughput assay for quantifying lipid accumulation in hepatocytes. Methods. 2027;257:32-42. doi:10.1016/j.ymeth.2026.10.006

BibTeX
@article{Ko2027,
  author = {Ko, Mun C D and Nowell, Cameron J and Turpin-Nolan, Sarah M and Flynn, Bernard L},
  title = {A live-cell medium-throughput assay for quantifying lipid accumulation in hepatocytes},
  journal = {Methods},
  year = {2027},
  volume = {257},
  pages = {32--42},
  doi = {10.1016/j.ymeth.2026.10.006}
}
Kostenlos starten →